NCT04507659 - Jaktinib Hydrochloride Tablets In The Treatment of Active Ankylosing Spondylitis | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

August 2, 2022

Study Completion Date

August 2, 2022

Conditions

Ankylosing Spondylitis

Interventions

DRUG

Jaktinib Hydrochloride Tablets

Morning: 2\*50mg simulated tablets and 1\*75mg Jaktinib Hydrochloride Tablets; Evening: 2\*50mg simulated tablets and 1\*75mg Jaktinib Hydrochloride Tablets.

DRUG

Jaktinib Hydrochloride Tablets

Morning: 1\*75mg simulated tablet, 2\*50mg Jaktinib Hydrochloride Tablets; Evening: 1\*75mg simulated tablet, 2\*50mg Jaktinib Hydrochloride Tablets.

DRUG

Placebo

Morning: 1\*75mg simulated tablet, 2\*50mg simulated tablets; Evening: 1\*75mg simulated tablet, 2\*50mg simulated tablets.

Trial Locations (1)

200011

Renji Hospital, Shanghai

All Listed Sponsors

lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY